Ocata Therapeutics Company
%20.jpg)
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Total Funding:
$82.5M
Headquarters:
Marlborough, Massachusetts, United States
Funding Status:
M&A
Employee Number:
11-50
Estimated Revenue:
$10M to $50M
Last Funding Type:
Venture - Series Unknown
Technology:
Regenerative Medicine
Investor Type:
For Profit
Investors Number:
13
Founded Date:
1-1
Industry:
Biotechnology, Health Care, Therapeutics